Andrea Linna is a partner at Wilson Sonsini Goodrich & Rosati, where she is a member of the firm’s digital health industry group and its healthcare practice. With more than a decade dedicated to healthcare law, Andrea exclusively represents digital health and healthcare IT clients, from emerging companies to established industry players, investors, and healthcare systems. Andrea guides her clients through the patchwork of federal and state laws that apply to digital health companies, addressing issues such as corporate practice of medicine, Stark Law compliance, Anti-Kickback Statute considerations, fee splitting, billing Medicare and Medicaid, contracting with commercial payors, value-based care arrangements, artificial intelligence, remote patient monitoring, online prescribing, scope of practice, and licensing requirements.

Rob Parr is a partner in the Boston office of Wilson Sonsini Goodrich & Rosati, where he leads the office’s information technology transactions practice. He represents companies in transactions focused on the exploitation of intellectual property rights and technology in a variety of industries. Rob represents many companies in the digital health industry in particular and plays a key role in the firm’s digital health initiative. He regularly drafts and negotiates a wide variety of complex commercial agreements, including services, distribution, strategic alliance and joint venture, supply, asset transfer, and intellectual property license agreements. Rob also represents clients with the intellectual property and commercial issues arising from financings, mergers, acquisitions, and initial public offerings. The International Association of Privacy Professionals has designated Rob as a Certified Information Privacy Professional (CIPP/US).

Eva Yin, Ph.D., M.P.H., is a partner in Wilson Sonsini Goodrich & Rosati’s FDA regulatory, healthcare, and consumer products practice. Her practice includes conducting FDA and healthcare regulatory due diligence for corporate transactions; providing legal counsel to manufacturers regarding FDA approval/clearance for various products—including medical devices, mobile apps, and drugs, FDA compliance, regulation of promotional materials and labeling, and manufacturer compliance under federal and state healthcare laws, e.g., the federal Anti-Kickback Statute (AKS), False Claims Act (FCA), Sunshine Act, state licensing laws, corporate practice of medicine, etc.; reviewing contracts and compliance policies for manufacturers; and providing legal analysis and risk assessment of business models and fee arrangements involving patient assistance programs, healthcare professionals, or hospitals/clinics under federal and state healthcare laws and regulations.

Shawn has almost a decade of in-house experience from a variety of healthcare and digital health settings, where he helped companies understand and operationalize healthcare regulatory requirements.